Issue Date: November 20, 2017
Avista boosts drug active capacity
Avista Pharma Solutions has doubled active pharmaceutical ingredient (API) production capacity at its Longmont, Colo., site. As part of the project, the company upgraded three API manufacturing suites and added a fourth. Avista was formed in 2015 when Ampersand Capital Partners combined Array BioPharma’s chemistry facility in Longmont with Scynexis’s contract R&D assets in Research Triangle Park, N.C., and Accuratus Lab Services in Eagan, Minn.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society